



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/833,222	04/11/2001	Ning Qin	ORT-1414	3034

27777 7590
PHILIP S. JOHNSON
JOHNSON & JOHNSON
ONE JOHNSON & JOHNSON PLAZA
NEW BRUNSWICK, NJ 08933-7003

12/27/2006

EXAMINER

SHAFER, SHULAMITH H

ART UNIT	PAPER NUMBER
	1647

SHORTENED STATUTORY PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE
3 MONTHS	12/27/2006	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

Office Action Summary	Application No.	Applicant(s)	
	09/833,222	QIN ET AL.	
	Examiner	Art Unit	
	Shulamith H. Shafer, Ph.D.	1647	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 11 October 2006.
 2a) This action is FINAL. 2b) This action is non-final.
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-5, 7, 13 and 23 is/are pending in the application.
 4a) Of the above claim(s) 23 is/are withdrawn from consideration.
 5) Claim(s) _____ is/are allowed.
 6) Claim(s) 1-3, 5, 7 and 13 is/are rejected.
 7) Claim(s) 4 is/are objected to.
 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date <u>9/13/01</u> . | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| | 6) <input type="checkbox"/> Other: _____ |

Detailed Action

Status of Application, Amendments, And/Or Claims:

Applicants' communication of 11 October 2006 (in response to Office Action of 15 August 2006) and the Terminal Disclaimer submitted on 11 October 2006 is acknowledged and made of record. Applicants communication of 9 June 2006 in response to Office Action of 7 December 2005 is acknowledged and made of record.

Claims 6 and 8 have been cancelled. Claims 1-3, 5 and 13 have been amended and the amendments made of record. New Claim 23 has been added and made of record. However, claim 23 is withdrawn from consideration. In the response of 1 March 2004 to the requirement for restriction, applicants elected Group I, drawn to nucleic acid molecule of SEQ ID NO:9, encoding SEQ ID NO:10, a vector, a host cell and a method of producing a protein for prosecution. Since applicant has received an action on the merits for the originally presented invention, this invention has been constructively elected by original presentation for prosecution on the merits. Accordingly, claim 23 is withdrawn from consideration as being directed to a non-elected invention. See 37 CFR 1.142(b) and MPEP § 821.03.

Claims 1-5, 7, and 13 are under consideration.

Withdrawn Objections/Rejections

Specification:

The objection to the specification as not being in compliance with the sequence rules, 37 CFR 1.821-1.825 is withdrawn in view of applicants indication that indicated sequences are, in fact, properly identified by sequence identifiers.

Claims:

All rejections of claims 6 and 8 are withdrawn. Applicants have cancelled the claims thereby rendering all rejections moot.

The provisional rejection of claims 1-5, 7 and 13 under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-3, 11, 12 and 18 of Application 10/119624 is withdrawn. The terminal disclaimer filed on 11 October 2006 disclaiming the terminal portion of any patent granted on this application which would extend beyond the expiration date of US Patent 7,157,248 has been reviewed and is accepted. The terminal disclaimer has been recorded.

The rejection Claim(s) 1-5, 7 and 13, under 35 U.S.C. 101/112 because the claimed invention is not supported by either a credible, substantial or specific asserted utility or a well established utility is withdrawn in view of Applicants' arguments.

The rejection of Claims 1 (e), (f) and (g), Claims 2, 3 and Claim 13(a) under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention is withdrawn in view of applicants' amendments to the claims.

The rejection of Claims 1, 3, 5-7 and 13 under 35 U.S.C. 102 (a) as being anticipated by Brown and Bertelli (22 March 2001, WO 01/19870 A2) is withdrawn. The rejection of Claim 2 under 35 U.S.C. 103(a) as being unpatentable over Brown and Bertelli (22 March 2001, WO 01/19870 A2) in view of Klugbauer et al. (1999, Journal of Neuroscience 19:684-691) is withdrawn. The Declaration of Dr. Ning Qin filed on 6 June 2006 under 37 CFR 1.131 is sufficient to overcome the Brown and Bertelli reference.

Maintained/New Objections/Rejections

Objections:

Claim 5 is objected to because of the following informalities: "wherein" is misspelled as "herein". Appropriate correction is required.

Claim 13 is objected to because of the following informalities: "capable" is misspelled as "coapable". Appropriate correction is required.

Art Unit: 1647

35 U.S.C. § 101

35 U.S.C. § 101 reads as follows:

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

Claim 7 is rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter.

Claim 7, as recited reads on host cells, including any eukaryotic cell. There is no limitation wherein the host cells are isolated or in culture, therefore the claims read on transfected cells in a human, and thus are not patentable subject matter. This rejection could be overcome by adding a limitation wherein the host cells are isolated or in culture.

35 U.S.C. § 112, Second Paragraph:

Claims 1-3, 5 and 13 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 1(a), and 5 have been amended to read "polypeptide having a sequence and biological activities substantially same.....". It is unclear what applicant intends by "substantially same". There is no art-accepted definition of the term, and the term is not defined in the specification; therefore, the metes and bounds of the claim cannot be determined.

Claims 2 and 3 are rejected as being vague and indefinite in reciting "Any of the nucleic acid molecules of claim 1". It is not clear how many of the molecules applicants intend. It is suggested that claims be amended to read "Any one of the.....".

Claim 13 is vague and indefinite in reciting "an $\alpha_2\delta$ -4 calcium channel". It is unclear what protein is intended to be encompassed to the term.

Claim 7 is included in this rejection as dependent upon rejected claims.

Art Unit: 1647

The rejection of Claim 1(d) for reciting "hybridizes under stringent conditions" is maintained for reasons of record and for reasons set forth below. Applicants traverse this rejection (Response of 9 June 2006, page 10). The reason for the traversal is that the specification provides detailed description and examples on pages 30-31.

Applicant's arguments have been fully considered but are not found to be persuasive for the following reasons: The specification discloses that any number of art-recognized methods may be used to facilitate accurate identification of nucleic acid targeting to a hybridizable probe (page 30, lines 21-23). The specification goes on to give an example and concludes with the statement "conditions for increasing the stringency of a variety of nucleotide hybridizations are well known in the art" (page 31, lines 15-16). However, the specification does not disclose specific hybridization conditions to be used in the instant invention; and unambiguous definition for "stringent conditions" has not been provided.

35 U.S.C. § 112, First Paragraph:

The rejection of amended Claim(s) 1-3, 5 and 13 for failing to comply with the enablement and written description requirement is maintained for reasons of record and for reasons set forth below. Applicants traverse this rejection (Response of 9 June 2006, page 9). The reason for the traversal is that the claims, as amended, are now directed to an isolated nucleic acid molecule encoding a polypeptide having a sequence and biological activities substantially same as a polypeptide of SEQ ID NO:10. Applicant's arguments have been fully considered but are not found to be persuasive for the following reasons: Nucleic acid molecules encoding polypeptides having a sequence and biological activities substantially same as a polypeptide of SEQ ID NO:10 are not enabled. Since the term "substantially same" does not have an art-accepted meaning and is not defined in the specification, undue experimentation would need to be undertaken by one of skill in the art to determine which of the possible sequences would encode a polypeptide having sequence and biological activity of the polypeptide

Art Unit: 1647

of SEQ ID NO:10. It would it would require undue experimentation of one of skill in the art to make and use the claimed invention to the full scope of the claims.

Furthermore, since the term "substantially same" does not have an art-accepted meaning and is not defined in the specification, the claims are drawn to a genus of nucleic acids that encode polypeptides having an undefined similarity to the polypeptide of SEQ ID NO:10. Only a nucleic acid molecule of SEQ ID NO:9 encoding a polypeptide of SEQ ID NO:10, but not the full breadth of the claims meet the written description provision of 35 U.S.C. 112, first paragraph.

The rejection of claim 7 under 35 U.S.C. 112, first paragraph because the specification, while being enabling for an isolated or cultured host cell comprising an expression vector, does not reasonably provide enablement for any generic host cell comprising an expression vector is maintained for reasons of record, and is also applied to claims 5 and 13. Please note, as stated in the previous office action, that this rejection could be overcome by amending the claims to recite, for example, "An isolated recombinant host cell..." because such an amendment would clarify that the claims are directed only to host cells which are to be made and used in culture. Applicants have failed to address this issue in their response.

35 U.S.C. § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-3, 5, 7 and 13 are rejected under 35 U.S.C. 102 (b) as being anticipated by Klugbauer et al (1999. Jnl of Neuroscience 19:684-691, cited in previous Office Action). Klugbauer et al. teach cloning and expression of two new genes encoding

Art Unit: 1647

proteins with essential properties of a calcium channel subunit, $\alpha_2\delta$ -2 and $\alpha_2\delta$ -3. The nucleic acid encoding $\alpha_2\delta$ -3 is 36.1% identical to the nucleic acid of SEQ ID NO:9. As can be seen by the enclosed sequence alignment, the nucleic acid taught by Klugbauer et al. comprises at least 15 sequential bases of polynucleotide of SEQ ID NO:9 (encoding polypeptide of SEQ ID NO:10). Thus, the teachings of Klugbauer et al. anticipate the limits of claim 1. The reference teaches isolation of RNA and cDNA library construction (page 684, 2nd column, last paragraph), thus anticipating the limitations of Claims 2 and 3. The reference teaches the preparation of expression vectors and the transfection of HEK293 cells (page 686, 1st column, 6th paragraph); absent evidence to the contrary, the $\alpha_2\delta$ -3 calcium channel subunit has “biological activities substantially same as polypeptide of SEQ ID NO:10”; thus claims 5 and 7 are anticipated. Therefore, the teachings of Klugbauer et al. anticipate all the limitations of Claims 1-3, 5 and 7.

Conclusions

Since new grounds for rejection have been presented, this action is non-final.

Claims 1-3, 7 and 13 are rejected.

Claim 4 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Art Unit: 1647

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shulamith H. Shafer, Ph.D. whose telephone number is 571-272-3332. The examiner can normally be reached on Monday through Friday, 8 AM to 5 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brenda Brumback can be reached on 571-272-0961. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

SHS



LORRAINE SPECTOR
PRIMARY EXAMINER

09/833, 222

Db 3053 TCGTGTACCAGCCGGCATCCGGAGGCCAACGGATCGGGATGCGGCCCTGCCAGA 3112
Qy 3110 AGGTATTTGTGGTGCAGCAGATTCCAAACAGTAACCTCCTCCCTGGTACAGACCCA 3169
Db 3113 AGGTATTTGTGGTGCAGCAGATTCCAAACAGTAACCTCCTCCCTGGTACAGACCCA 3172
Qy 3170 CCTGTGACTGCAGCATCTTCCCACCACTGCTGCAGGAGGGCACAGAAGTCAAATATAATG 3229
Db 3173 CCTGTGACTGCAGCATCTTCCCACCACTGCTGCAGGAGGGCACAGAAGTCAAATATAATG 3232
Qy 3230 CCTCTGTCAAATGTGACCGGATGCGCTCCAGAACGACTCCGCCGGGACCCAGACTCCTGCC 3289
Db 3233 CCTCTGTCAAATGTGACCGGATGCGCTCCAGAACGACTCCGCCGGGACCCAGACTCCTGCC 3292
Qy 3290 ACGCCTTCATCCAGAGGTGCGGTTGAGG 3319
Db 3293 ACGCCTTCATCCAGAGGAGAATGCCAGG 3322

RESULT 15

MMU010949

LOCUS MMU010949 3710 bp mRNA linear ROD 22-JAN-1999
DEFINITION Mus musculus mRNA for voltage gated calcium channel alpha-2-delta-C subunit.
ACCESSION AJ010949
VERSION AJ010949.1 GI:4186072
KEYWORDS calcium channel alpha-2-delta-C subunit.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE 1
AUTHORS Klugbauer,N., Lacinova,L., Marais,E., Hobom,M. and Hofmann,F.
TITLE Molecular diversity of the calcium channel alpha₂delta subunit
JOURNAL J. Neurosci. 19, 648-691 (1999)
REFERENCE 2 (bases 1 to 3710)
AUTHORS Klugbauer,N.
TITLE Direct Submission
JOURNAL Submitted (10-SEP-1998) Klugbauer N., Institut fuer Pharmakologie und Toxikologie, Technische Universitaet Muenchen, Biedersteiner Str. 29, 80802, GERMANY
FEATURES Location/Qualifiers
source 1..3710
/organism="Mus musculus"
/mol_type="mRNA"
/db_xref="taxon:10090"
/tissue_type="brain"
/dev_stage="adult"
CDS 98..3373
/codon_start=1
/product="calcium channel alpha-2-delta-C subunit"
/protein_id="CAA09423.1"
/db_xref="GI:4186073"
/db_xref="GOA:Q9Z1LS"
/db_xref="SPTREMBL:Q9Z1L5"
/translation="MAGPGSLCCASRGASALLATALLYAALGDVVRSEQQIPLSVVKL WASAFGEIKSIAAKYSGSQLIQQKYKEYKDVIAEEIDGLQLVKKLAKIMBEMFHKK SEAVRRLVEAAEAEAHLKHEFDADLQYEYFNAVLINERDKDGNFLELGKEFILAPNDHF NNLPVNISLSDVQVPNTNMNKDAPIAVNGVWSESLNKFVVDNFDRDPSLIWQYFGSAK GFFRQYPGIKWEPDENGVIAFDCCRNRKWYIQATSPKDVVILVDVSGSMKGLRLTIAK QTVSSILDTLGDDDFNIITYNEELHYVEPCLNGLTVQADRTNKEHFRHLDKLFAGK IGMIDIALNEAFNISLDFNHTGGQSICCSQAIMLITDGAVIDTYDTIFAKYNWDRKVRI FTYLIGREAAFADNLKWMACANKGFTQISTLADVQENVMYELHVLSPRKVIDQEHDV VWTEAYIDSTLPQAQKLADDQGVLMLTTVAMPVFSKQNETRSKGILLGVVGTDPVKE LLKTIPKYKLGIIHGYAFAITNNGYILTHPELRLPYEEGKRRKPQYSSVDSLSEBEWED RDDVLRNAMVNRKTKGKFSMEVKTVDKGKRVLVMTNDYYTDIKGTPFSLGVALSRGH GKYYFRGNVTIEEGLHDLEHPDVS LADEWSYCNTDLHPEHRHLSQLEAIKLYLKGKBP LLQCDKELIQEVLFDAVVSAPIEAYWTSLALNKSSENSDKGVVAFLGTRTGLSRINLF VGAEQLTNQDFLKAGDKENIFNADHFPWLWYRAAEQIAQSFVYSIPFSTGTVNKSNNV TASTSIQLLDERKSPVVAAVGIQMKEFFQRKFWTASRQCASLDGKCSISCDDETVCN YLIDNNNGFILVSEDYTQTDGFGEVEGAVMNKLTMGSFKRITLYDYQAMCRANKESS

09/833,222

DSAHGLDPYKAFLSAAKWIMTELVLPLVEFNILCSWWHSDMTAKAQLKQTLPCDTE
YPAFVSERTIKEITGNIACEDCSKSFVIQQIPSSNLPMVVDSSCLCESVAPITMAPI
EIRYNESLKERCERLKAQKIRRRPESCHGFHPEENARECGGASSLQAQALLLPLVSSL
FSR"

ORIGIN

Query Match 36.1%; Score 1258.2; DB 10; Length 3710;
Best Local Similarity 64.1%; Pred. No. 5.9e-244;
Matches 1984; Conservative 0; Mismatches 1068; Indels 45; Gaps 4;

Qy 225 AGTGAAGCTATGGGCTGACACCTTCGGCGGGACCTGTATAACACTGTGACCAAATACTC 284
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 220 AGTGAAGCTGTGGCCTCCGCTTTGGTGGGGAGATAAAATCCATCGCTGCCAAGTACTC 279
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 285 AGGCTCTCTTGTGCGAGAAGAAGTACAAGGATGTGGAGTCCAGTCTGAAGATCGAGGA 344
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 280 GGGCTCCCAGCTCTGCAAAAGAAAATACAAGAGTATGAGAAGGACCTGCCATTGAAGA 339
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 345 GGTGGATGGCTTGGAGCTGGTGAGGAAGTCTCAGAGGACATGGAGAACATGCTGCGGAG 404
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 340 AATCGACGGTCTCAAATGGTGAAGAAGTTGGCTAAAATCATGGAGGAGATGTTCCACAA 399
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 405 GAAAGTCGAGCGGTCCAGAAATCTGGTGAAGCTGCCAGGGGCCACCTGAACCACGA 464
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 400 GAAGTCCGAGGCAGTGAGGCCCTTGTGGAGGCTGCAGAGGAGGACACCTGAAACATGA 459
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 465 ATTCAATGAATCCCTGGTGTGACTATTACAACCTGGTCTGATCAACGAGAGGGACGA 524
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 460 ATTGATGCTGACTTGAGCTATGAATACTTCAATGCTGTGCTGATCAACGAGAGGGACAA 519
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 525 GAAGGGCAACTTCGTGGAGCTGGCGCCAGTTCCCTCTGGAGTCCAATGCTCACTTCAG 584
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 520 AGACGGGAACCTTTGGAATTGGAAAGGAATTCACTTAGCCCCAATGACCATTAA 579
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 585 CAACCTGCCGTGAACACCTCCATCAGCAGCGTGCAGCTGCCACCAACGTGTAACACAA 644
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 580 TAATTGCTGTGAACATCAGTCTGAGTGTGCAAGTGCAACATGTACAACAA 639
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 645 AGACCCAGATTTAAATGGAGTCTACATGTCAGCCTGAATGCTGCTTCGTGGA 704
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 640 AGATCCTGCCATTGCAATGGAGTGTATTGGCTGATCTAAACAAAGTTTGTGGA 699
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 705 GAACTTCCAGAGAGACCCAACTGACCTGGCAATATTGGCAGTGCACACTGGATTCTT 764
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 700 TAACTTGATGGGATCCGTCTCATATGCCAGTACTTGGAAAGTGCAAGGGCTTTT 759
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 765 CAGGATCTATCCAGGTATAAAATGGACACCTGATGAGAATGGAGTCATTCTTGTACTG 824
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 760 CAGACAGTACCCAGGGATTAAATGGGAAACAGATGAGAATGGAGTCATTGCCCTTGACTG 819
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 825 CCGAAACCGGGCTGGTACATTCAAGCTGCTACTTCTCCAAGGACATAGTGTATTGGT 884
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 820 CAGAACAGAAAATGGTACATCCAGGCAGCAGTCTCCAAGGATGGTGTGTCATTGGT 879
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 885 GGACGTGAGCGGCAGTGAAGGGCTGAGGGATGACTATTGCAAGCACACCATCACAC 944
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 880 GGACGTCACTGGAGCATGAAGGACTCCGCTTGACCATCGCAAGCAACAGTGTCTTC 939
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 945 CATCTGGACACCCCTGGGGAGAATGACTTCGTTAATATCATAGCGTACAATGACTACGT 1004
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 940 AATACTGGATACTCTGGGTGATGACTCTTCAACATCATCAGTATAACGAAGAGCT 999
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 1005 CCATTACATCGAGCCTTGTAAAGGATCCTCGTCAGGGCGACCGAGACAATCGAGA 1064
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 1000 TCACTATGTGAAACCTTGTGAAACGGAAACACTGGTCAAGCTGACAGGACCAACAAGGA 1059
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 1065 GCATTTCAAACCTGCTGGTGGAGGAGTTGATGGTCAAAGGTGTGGGGGTCGTGGACCAAGC 1124
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 1060 GCACTTCAGGGAGCATTTGGACAAACTTTGCCAAAGGGATTGGAATGCTGGATATCGC 1119
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Qy 1125 CCTGAGAGAAGCCTCCAGATCCTGAAGCAGTTCCAAGAGGCCAAGCAAGGAAGCCTCTG 1184

Db	1120	ACTGAACGAGGCCCTCAACATACTGAGCATTCAACCACACTGGACAAGGAAGCATTTG	1179
Qy	1185	CAACCAGGCCATCATGCTCATCGCGACGGCCGTGGAGGACTACGAGCCGTGTTGA	1244
Db	1180	CAGCAGGCCATCATGCTCATACTGATGGGCAGTGGACACCTATGATACCATTTG	1239
Qy	1245	GAAGTATAACTGGCCAGACTGTAAGGCCAGTTCACTTACCTCATGGAGAGAAGT	1304
Db	1240	AAAATATAATTGGCCAGACCGAAAGGTCGAATCTTACTTACCTCATGGACGGAGGC	1299
Qy	1305	GTCTTTGCTGACCGCATGAAGTGGATTGCATGCAACAACAAGGCTACTACACCGAGAT	1364
Db	1300	TGCTTTGCCGACAATCTCAAGTGGATGGCTTGCTAACAAAGGATTTCACCCAGAT	1359
Qy	1365	CTCAACGCTGGCGACACCCAGGAGAACGTGATGGAATACCTGCACGTGCTCAGCCGCC	1424
Db	1360	CTCACCTGGCTATGTGCGAGAAAATGTGATGGAATACCTCATGCTTAGCGACCC	1419
Qy	1425	CATGGTCATCAACACAGGACGACATCATCTGGACAGAGGCCATATGGACAGCAAGCT	1484
Db	1420	TAAAGTCATTGACCAAGGAGCATGATGTTGTTGGACCGAAGCGTACATTGACACGCC	1479
Qy	1485	CCTCAGCTCGC-----AGGCTCAGAGCCTGACACTGCTCACCACTGTGGCCAT	1532
Db	1480	CCCTCAGGCTCAAAGCTTGCTGATGATCAGGGCTCGCTTGATGACCACGGTGGCCAT	1539
Qy	1533	GCCAGTCTCAGCAAGAAGAACGAAACCGGATCCCCTGGCATTCCTGGGTGGTGGGG	1592
Db	1540	GCCTGTGTTAGTAAGCAGAACGAAACTAGGTCAAAGGGATTCCTGGGTGGTGGTGG	1599
Qy	1593	CTCAGATGTGGCCCTGAGAGAGCTGATGAAGCTGGGCCCGTACAAGCTGGAGTGCA	1652
Db	1600	CACAGATGTCCCAGTTAAAGAGCTCTGAAGACCATCCCCAATACAAGTTAGGAATTCA	1659
Qy	1653	CGGATACGCCCTCTGAAACACCAACAATGGCTACATCCTCCATCCGACCTCCGCC	1712
Db	1660	TGGTTACGCCCTCGCCATCAGGATAATGGATATATCCTGACGCCACCGGAGCTCAGGCC	1719
Qy	1713	CCTGTACAGAGAGGGAAAGAAACTAAAAACCCAAACCTAATCACACAGTGTGGATCTCTC	1772
Db	1720	ACTGTATGAAGAAGGAAAAAAACCGGA---GGAAACCCAATCACAGTGTGGATCTCTC	1776
Qy	1773	CGAAGTGGAGTGGAAAGACCAGGCTGAATCTGTGAGAACAGCCATGATCAATAGGGAAAC	1832
Db	1777	TGAAGTCAGTGGAAAGACCGGGATGATGTTACGAAATGCCATGGTAAATCGGAAGAC	1836
Qy	1833	ACGTACTCTCGATGGATGTGAAGGTTCCGATGGATAAAGGGAAAGCGAGTCTTCTCT	1892
Db	1837	TGGGAAATTCTCCATGGAAGTGAAGAAGACCGTGGACAAAGGGAAACGGGTTTGGTGAT	1896
Qy	1893	GACCAATGACTACTCTTCACGGACATCAGCGACACCCCTTCAGTTGGGGCGGTGCT	1952
Db	1897	GACCAATGACTACTACTACAGACATCAAGGGTACTCCTTCAGTTAGGTGTGGCGCT	1956
Qy	1953	GTCCCGGGCCACGGGAAATACATCCTCTGGGAACACGTCTGTGGAAAGAAGGCCGCA	2012
Db	1957	CTCCAGGGCCATGGGAAATACTCTCCGAGGGATGTAACCATTAAGAAGAAGGCCCTCCA	2016
Qy	2013	TGACTTGTCTCACCCAGACCTGGCCCTGGCCGGTACTGGATCTACTGCATCACAGATAT	2072
Db	2017	TGACTTGAACATCCTGACGTGCTTGGCAGATGAAATGGCTTACTGCAACACTGACCT	2076
Qy	2073	TGACCCAGACCACCGGAAGCTCAGCCAGCTAGAGGCCATGATCCGCTTCTCACCGGAA	2132
Db	2077	GCACCCAGACGCCATCTATCTCAACTGAAAGCCATTAAAGCTCTACCTCAAAGGCAA	2136
Qy	2133	GGACCCAGACCTGGAGTGTGACGGAGGAGCTGGTCCGGAGGTGCTGTTGACCGGTGGT	2192
Db	2137	GGAGCCTCTGCTTCAATGTGACAAAGAATTGATCAAGAAGTCTTGTGCTGTGGT	2196

Qy 2193 GACAGCCCCATGGAAGCCTACTGGACAGCGCTGGCCCTAACATGTCCGAGGAGTCTGA 2252
 ||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
 Db 2197 GAGCGCCCCTATTGAAAGCCTATTGGACGAGCCTGGCCCTAACAAATCTGAGAATTCTGA 2256
 ||| ||||| ||||| ||||| ||||| ||||| |||||
 Qy 2253 ACACGTGGTGGACATGGCCTTCCTGGGACCCGGCTGGCCTCTGAGAACAGCAGCTTGT 2312
 ||| ||||| ||||| ||||| ||||| ||||| |||||
 Db 2257 CAAGGGTAGAGGTCGCCTCCCTCGCACAGGCCCTCAAGAACATCAACCTGT 2316
 ||| ||||| ||||| ||||| ||||| |||||
 Qy 2313 CGTGGGCTCCGAGAAGGTCTCCGACAGGAAGTCTGTACACCTGAGGACGGAGGCCAGCGT 2372
 ||| ||||| ||||| ||||| ||||| ||||| |||||
 Db 2317 TGTGGGGCGAACAACTACCAATCAGGACTTCTGAAGGCTGGAGAACAAAGAGAACAT 2376
 ||| ||||| ||||| ||||| ||||| |||||
 Qy 2373 GTTCACCCCTGGACCGCTTCCCGCTGTGGTACCGCCAGGCCCTCAGAGCATCCTGCTGGCAG 2432
 ||| ||||| ||||| ||||| ||||| ||||| |||||
 Db 2377 TTAAATGCCGATCATTTCCCTCTGGTACAGAACAGCTGCCAGCAGATCGCAGGAAG 2436
 ||| ||||| ||||| ||||| ||||| |||||
 Qy 2433 CTTCGTCTTCAACCTCCGCTGGCAGAACAGGACAGAACAGTGGGGTAACCCATGGTGGT 2492
 ||| ||||| ||||| ||||| ||||| ||||| |||||
 Db 2437 CTTTGCTATTCATCCCCTCAGCACAGAACAGTC-----ACAAAAGCAATGTGGT 2490
 ||| ||||| ||||| ||||| ||||| |||||
 Qy 2493 GACGGCAAGCACAGCTGTGGCGTGACCGTGGACAAGAGGACAGCCATTGCTGCAGCCGC 2552
 ||| ||||| ||||| ||||| ||||| ||||| |||||
 Db 2491 GACAGCAAGTACCTCCATCCAGCTCCTGGATGAGCGGAATCTCCCGTGGCAGCTGT 2550
 ||| ||||| ||||| ||||| ||||| |||||
 Qy 2553 GGGCGTCAAATGAAGCTGAAATTCTCCAGCGCAAATTCTGGCGGCAACGCCAGTGT 2612
 ||| ||||| ||||| ||||| ||||| |||||
 Db 2551 AGGCATTAGATGAAACTTGAATTCTCCAAAGGAAGTCTGGACTGCCAGCAGACAGTG 2610
 ||| ||||| ||||| ||||| ||||| |||||
 Qy 2613 CAGCACTGTGGATGGGCCGTACACACAGAGCTGCCAGGACAGTGTACTGGACTGCTTCGT 2672
 ||| ||||| ||||| ||||| ||||| |||||
 Db 2611 TGCCTCCCTGGATGGCAAATGCTCCATAACCTGCGATGACGAGACTGTGAACTGTTACCT 2670
 ||| ||||| ||||| ||||| ||||| |||||
 Qy 2673 CATCGACAACACGGGTTCTCTGATCTCAAGAGGTCCCAGAGACGGGAAGATTCT 2732
 ||| ||||| ||||| ||||| ||||| |||||
 Db 2671 TATAGACAATAACGGATTCTCTGGTGTGAAAGACTACACACAGACTGGAGATTTTT 2730
 ||| ||||| ||||| ||||| |||||
 Qy 2733 GGGGGAGGTGGATGGTGTCTGCTGACCCAGCTGCTCAGCATGGGGTGTTCAGCCAAGT 2792
 ||| ||||| ||||| ||||| ||||| |||||
 Db 2731 TGGTGGAGGTGGAAAGGAGCTGTGATGAAACAGTTGTTAACATGGTTCTTTAAAGAAT 2790
 ||| ||||| ||||| ||||| |||||
 Qy 2793 GACTATGTATGACTATCAGGCCATGTGAAACCCCTCGAGTCACCACACAGTGCAGCCCA 2852
 ||| ||||| ||||| ||||| ||||| |||||
 Db 2791 AACCTTGTACGACTACCAAGCCATGTGAGGCAACAGGAGAGCAGTGACAGTGCCTCA 2850
 ||| ||||| ||||| ||||| |||||
 Qy 2853 GCCCCCTGGTCAGCCCAATTCTGCTTCTTGACGGCGACAGTGGCTGCTGCAGGAGCT 2912
 ||| ||||| ||||| ||||| ||||| |||||
 Db 2851 TGGACTTCTGGACCCCTATAAGGCTTCTCTGCAAGGATAATGACGGAACT 2910
 ||| ||||| ||||| ||||| |||||
 Qy 2913 GGTGCTGTTCTGCTGGAGTGGAGTGTCTGGGCTCTGGTACGACAGAGGGGCCAGGC 2972
 ||| ||||| ||||| ||||| |||||
 Db 2911 TGTCTGTTCTGGAGTTAACCTGTCAGTTGGACTCCGACATGACAG----- 2966
 ||| ||||| ||||| |||||
 Qy 2973 CAAAAGTGTCTTCCATCACTCCACAAACACAAGAACAGCAGGCCGCTGCAGCCCTGCCA 3032
 ||| ||||| ||||| ||||| |||||
 Db 2967 -----CTAAAGCCAGAAACTGAACAGACCCCTGGAACCTTGTGA 3006
 ||| ||||| |||||
 Qy 3033 CACGGAGTACCCGTGTCGTGATCCAGCCGCCATCGGGAGGCCACGGGATCGTGG 3092
 ||| ||||| ||||| ||||| |||||
 Db 3007 TACTGAATACCCAGCCTTGTGTTCTGAACGCCACATCAAGGAGACCAAGGGAACATTG 3066
 ||| ||||| |||||
 Qy 3093 GTGCGGGCCCTGCCAGAAGGTATTTGTGGTGCAGCAGATTCCAAACAGTAACCTCCCT 3152
 ||| ||||| ||||| ||||| |||||
 Db 3067 TTGCGAAGACTGCTCCAAGTCTCGTCATCCAGCAAATCCCGAGTAGCAATCTGTTCA 3126
 ||| ||||| |||||
 Qy 3153 CCTGGTGACAGACCCACCTGTGACTGCAGCATCTCCACCAAGTGTGAGGAGGCCAC 3212
 ||| ||||| ||||| ||||| |||||
 Db 3127 GGTGGTGGTGAGCAGTAGCTGTCTGTGAGTCCTGGCTCCCTATAACCATGGCACCCAT 3186
 ||| ||||| |||||
 Qy 3213 AGAAGTCAAATATAATGCCTCTGTCAAATGTGACCGGATGCGCTCCAGAACGCTCCCG 3272
 ||| ||||| ||||| |||||
 Db 3187 TGAAATCAGGTATAATGAATCCCTAACGTGTGAAACGGTAAAGGCTCAGAACATCAGACG 3246

Qy 3273 GCGACCAGACTCCTGCCACGGCTTCCATCCAGAGGTG 3309
||| ||||| ||||||||| ||||| ||||| |||||
Db 3247 ACGTCCAGAATCCTGCCACGGCTTCCATCCTGAGGAG 3283